name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2

text: 100 nM Vorinostat (SAHA, MK0683)

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946

status: PUBLIC

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

characteristic: INSDC first public

characteristic: INSDC last update

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

tag: attribute

characteristic: age

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2

characteristic: description

text: 100 nM SGC 0946

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2

text: 100 nM Apicidin

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2

text: 100 nM BML-266

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM B2

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM B2 in position E10 in plate 2

text: 100 nM B2

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2

text: 100 nM NSC-3852

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2

text: 100 nM RGFP966

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2

characteristic: description

text: 100 nM RVX-208

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2

text: 100 nM Nexturastat A

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2

text: 100 nM Tubastatin A

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2

text: 100 nM VX-680 (Tozasertib, MK-0457)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2

text: 100 nM UNC1215

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2

text: 100 nM Suberoyl bis-hydroxamic acid

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2

text: 100 nM Piceatannol

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2

text: 100 nM BIX-01294·3HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2

text: 100 nM Aminoresveratrol sulfate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2

characteristic: description

text: 100 nM Bromosporine

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl

text: Netherlands Cancer Institute

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2

text: 100 nM PJ34 HCl

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2

text: 100 nM Filgotinib (GLPG0634)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2

text: 100 nM Lomeguatrib

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2

text: 100 nM Entinostat (MS-275)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2

text: 100 nM AZD1208

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2

text: 100 nM Nullscript

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2

text: 100 nM Fluoro-SAHA

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2

text: 100 nM Butyrolactone 3

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2

characteristic: description

text: 100 nM BML-281

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2

text: 100 nM IOX1

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2

text: 100 nM CPI-203

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2

text: 100 nM Rocilinostat (ACY-1215)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2

text: 100 nM Pacritinib (SB1518)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2

text: 100 nM Olaparib (AZD2281, Ku-0059436)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2

text: 100 nM (+)-JQ1

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2

text: 100 nM Isonicotinamide

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2

text: 100 nM Valproic acid hydroxamate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2

characteristic: description

text: 100 nM CTPB

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2

text: 100 nM Triacetylresveratrol

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1

text: 1 µM Belinostat (PXD101)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1

text: 1 µM Danusertib (PHA-739358)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1

text: 1 µM SNS-314 Mesylate

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1

text: 1 µM JNJ-7706621

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1

text: 1 µM CCT129202

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1

text: 1 µM AG-14361

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1

text: 1 µM Tubastatin A HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1

characteristic: description

text: 1 µM CUDC-907

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1

text: 1 µM CI994 (Tacedinaline)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1

text: 1 µM Entacapone

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1

text: 1 µM Iniparib (BSI-201)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1

text: 1 µM Mocetinostat (MGCD0103)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1

text: 1 µM Ruxolitinib (INCB018424)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1

text: 1 µM Hesperadin

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1

text: 1 µM LY2784544

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1

characteristic: description

text: 1 µM NVP-BSK805 2HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1

text: 1 µM MK-5108 (VX-689)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1

text: 1 µM RG108

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1

text: 1 µM Sodium Phenylbutyrate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1

text: 1 µM PCI-24781 (Abexinostat)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1

text: 1 µM SRT1720

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1

text: 1 µM CYC116

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1

text: 1 µM Resveratrol

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1

text: 1 µM EX 527 (Selisistat)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1

characteristic: description

text: 1 µM SGI-1776 free base

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1

text: 1 µM TG101209

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM M344

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM M344 in position C09 in plate 1

text: 1 µM M344

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1

text: 1 µM Tranylcypromine (2-PCPA) HCl

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1

text: 1 µM LAQ824 (Dacinostat)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1

text: 1 µM INO-1001

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1

text: 1 µM ENMD-2076

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1

text: 1 µM Droxinostat

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1

characteristic: description

text: 1 µM Azacitidine

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1

text: 1 µM AZ 960

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1

text: 1 µM Resminostat

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1

text: 1 µM I-BET151 (GSK1210151A)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1

text: 1 µM WHI-P154

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1

text: 1 µM 3-Aminobenzamide

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1

text: 1 µM Quisinostat (JNJ-26481585)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1

text: 1 µM Alisertib (MLN8237)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1

text: 1 µM CUDC-101

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1

characteristic: description

text: 1 µM Aurora A Inhibitor I

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1

text: 1 µM PCI-34051

characteristic: drug

text: patient with chronic myelogenous leukemia (CML)

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387

text: Netherlands Cancer Institute

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1

text: 1 µM CYT387

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1

text: 1 µM TAK-901

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1

text: 1 µM PJ34

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1

text: 1 µM Procainamide HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1

text: 1 µM Rucaparib (AG-014699,PF-01367338)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1

text: 1 µM AT9283

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1

characteristic: description

text: 1 µM Decitabine

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1

text: 1 µM PHA-680632

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1

text: 1 µM KW-2449

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1

text: 1 µM Tubacin

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1

text: 1 µM AMG-900

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1

text: 1 µM WP1066

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1

text: 1 µM S-Ruxolitinib (INCB018424)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1

text: 1 µM Tofacitinib (CP-690550) Citrate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1

text: 1 µM MLN8054

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1

characteristic: description

text: 1 µM AG-490 (Tyrphostin B42)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1

text: 1 µM PFI-1 (PF-6405761)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1

text: 1 µM MC1568

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1

text: 1 µM AZD1480

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1

text: 1 µM AR-42

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1

text: 1 µM TG101348 (SAR302503)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1

text: 1 µM Sirtinol

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1

text: 1 µM IOX2

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1

text: 1 µM AZD2461

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1

characteristic: description

text: 1 µM ZM 447439

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1

text: 1 µM Barasertib (AZD1152-HQPA)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1

text: 1 µM 2-Methoxyestradiol (2-MeOE2)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1

text: 1 µM Pracinostat (SB939)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1

text: 1 µM Givinostat (ITF2357)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1

text: 1 µM Quercetin

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1

text: 1 µM CCT137690

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1

text: 1 µM CEP-33779

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1

text: 1 µM Romidepsin (FK228, Depsipeptide)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1

characteristic: description

text: 1 µM XL019

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2

text: 1 µM Zebularine

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2

text: 1 µM OG-L002

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2

text: 1 µM TMP269

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2

text: 1 µM ZM 39923 HCl

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2

text: 1 µM Veliparib (ABT-888)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2

text: 1 µM CX-6258 HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2

text: 1 µM 2,4-Pyridinedicarboxylic Acid

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2

text: 1 µM ITSA-1

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2

characteristic: description

text: 1 µM AGK2

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2

text: 1 µM Oxamflatin

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2

text: 1 µM 3-Deazaneplanocin A (DZNeP)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2

text: 1 µM SGC-CBP30

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2

text: 1 µM EPZ004777

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2

text: 1 µM SMI-4a

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2

text: 1 µM FG-4592

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2

text: 1 µM BMN 673

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2

text: 1 µM Garcinol

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2

characteristic: description

text: 1 µM Tranylcypromine hemisulfate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2

text: 1 µM Salermide

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2

text: 1 µM Suramin·6Na

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2

text: 1 µM EPZ-6438

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2

text: 1 µM MM-102

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2

text: 1 µM OTX015

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2

text: 1 µM BIX 01294

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2

text: 1 µM Panobinostat (LBH589)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2

text: 1 µM EPZ5676

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2

characteristic: description

text: 1 µM Splitomicin

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2

text: 1 µM Valproic acid

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2

text: 1 µM MC-1293

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278

text: Netherlands Cancer Institute

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2

text: 1 µM BML-278

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM C646

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM C646 in position D02 in plate 2

text: 1 µM C646

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2

text: 1 µM SGI-1027

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2

text: 1 µM UNC669

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2

text: 1 µM UPF 1069

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2

text: 1 µM Trichostatin A (TSA)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2

characteristic: description

text: 1 µM GSK J4 HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2

text: 1 µM BML-210

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2

text: 1 µM Nicotinamide

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2

text: 1 µM Anacardic acid

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2

text: 1 µM NCH-51

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2

text: 1 µM I-BET-762

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2

text: 1 µM RG2833 (RGFP109)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2

text: 1 µM ME0328

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2

text: 1 µM Scriptaid

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2

characteristic: description

text: 1 µM Vorinostat (SAHA, MK0683)

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946

text: Netherlands Cancer Institute

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2

text: 1 µM SGC 0946

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2

text: 1 µM Apicidin

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2

text: 1 µM BML-266

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM B2

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM B2 in position E10 in plate 2

text: 1 µM B2

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2

text: 1 µM NSC-3852

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2

text: 1 µM RGFP966

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2

text: 1 µM RVX-208

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2

text: 1 µM Nexturastat A

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2

characteristic: description

text: 1 µM Tubastatin A

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2

text: 1 µM VX-680 (Tozasertib, MK-0457)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2

text: 1 µM UNC1215

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2

text: 1 µM Suberoyl bis-hydroxamic acid

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2

text: 1 µM Piceatannol

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2

text: 1 µM BIX-01294·3HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2

text: 1 µM Aminoresveratrol sulfate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2

text: 1 µM Bromosporine

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2

text: 1 µM PJ34 HCl

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2

characteristic: description

text: 1 µM Filgotinib (GLPG0634)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2

text: 1 µM Lomeguatrib

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2

text: 1 µM Entinostat (MS-275)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2

text: 1 µM AZD1208

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2

text: 1 µM Nullscript

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2

text: 1 µM Fluoro-SAHA

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2

text: 1 µM Butyrolactone 3

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2

text: 1 µM BML-281

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2

text: 1 µM IOX1

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2

characteristic: description

text: 1 µM CPI-203

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2

text: 1 µM Rocilinostat (ACY-1215)

characteristic: drug

characteristic: isolate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2

text: 1 µM Pacritinib (SB1518)

text: Homo sapiens

text: cell culture

text: female

characteristic: sex

text: bone marrow

characteristic: tissue

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)

text: Netherlands Cancer Institute

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2

text: 1 µM Olaparib (AZD2281, Ku-0059436)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens

characteristic: title

characteristic: transfected plasmid


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: SRA accession

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2

text: 1 µM (+)-JQ1

text: Homo sapiens

characteristic: organism

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide

characteristic: External Id

text: Netherlands Cancer Institute

characteristic: INSDC center name

text: live

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2

text: 1 µM Isonicotinamide

text: patient with chronic myelogenous leukemia (CML)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate

text: Netherlands Cancer Institute

characteristic: INSDC first public

characteristic: INSDC last update

text: live

text: Human

text: Bas van Steensel, Division of Gene Regulation, Netherlands Cancer Institute

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2

text: 1 µM Valproic acid hydroxamate

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB

text: Netherlands Cancer Institute

characteristic: INSDC secondary accession

text: live

characteristic: INSDC status

text: Human

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2

text: 1 µM CTPB

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: NCBI submission model

characteristic: NCBI submission package

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2

text: 1 µM Triacetylresveratrol

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens


name: K562 ddCas9 RSTP2 clone5 treated with 10 uM Belinostat (PXD101)

text: Netherlands Cancer Institute

text: live

text: Human

characteristic: age

text: K562-17 ddCas9 DSB-TRIP (RSTP2) clone 5

text: Chronic Myeloid Leukemia

text: Sample from drug screen treated with 10 µM Belinostat (PXD101) in position A02 in plate 1

characteristic: description

text: 10 µM Belinostat (PXD101)

text: Homo sapiens

text: cell culture

text: female

text: bone marrow

text: Human sample from Homo sapiens